Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of EDG-5506 in ambulatory adults and adolescents with Becker muscular dystrophy
MOH_2024-05-02_013390Phase 2Recruiting
- Sponsor
- Edgewise Therapeutics
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD) comparing EDG-5506 with Placebo (2 arms). Primary endpoints: Safety and Efficacy. Started Apr 2024; status: recruiting.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on MOH_2024-05-02_013390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-02_013390.